Lucid Diagnostics (LUCD) Cash from Investing Activities (2021 - 2026)
Lucid Diagnostics' (LUCD) quarterly Cash from Investing Activities came in at -$215000.0 in Q1 2026, down 131.18% YoY from $689482.8 in Q1 2025, and down 321.57% on a QoQ basis from -$51000.0 in Q4 2025.
Lucid Diagnostics (LUCD) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Lucid Diagnostics (LUCD) has 6 years of Cash from Investing Activities data on file, last reported at -$215000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 131.18% year-over-year to -$215000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319000.0 (up 54.56% YoY) and the FY2025 annual result came in at -$197000.0, up 69.5% from the prior year.
- Cash from Investing Activities eased to -$215000.0 in Q1 2026, from -$51000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$14000.0 in Q3 2023 to a low of -$2.4 million in Q2 2022.
- A 5-year average of -$336687.5 and a median of -$120500.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 243500.0% — and 2023, when it jumped 99.38%.
- Tracing LUCD's Cash from Investing Activities over 5 years: stood at -$203000.0 in 2022, then climbed by 13.79% to -$175000.0 in 2023, then sank by 48.0% to -$259000.0 in 2024, then soared by 80.31% to -$51000.0 in 2025, then slumped by 321.57% to -$215000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$215000.0 (Q1 2026), -$51000.0 (Q4 2025), and -$28000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Lucid Diagnostics | 176.73 Mn | 143.33 Mn | 55,000.00 | -21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21,000.00 |
| Jun 30, 2026 | -21,000.00 |
| Mar 31, 2026 | -215,000.00 |
| Mar 31, 2026 | -215,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Sep 30, 2024 | -350,000.00 |
| Sep 30, 2024 | -350,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -175,000.00 |
| Dec 31, 2023 | -175,000.00 |